Burke, VA, United States of America

Suresh Bhatia



Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 46(Granted Patents)


Company Filing History:


Years Active: 1995-1999

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Suresh Bhatia: Innovator in Hydrophobic Taxane Derivatives

Introduction

Suresh Bhatia is a notable inventor based in the United States. He has made significant contributions to the field of pharmaceuticals, particularly in the development of taxane derivatives. His innovative work focuses on enhancing the stability and efficacy of these compounds for medical applications.

Latest Patents

Suresh Bhatia holds a patent for his invention titled "Hydrophobic Taxane Derivatives." This invention provides a taxane derivative of formula (I), wherein a hydrophobic organic moiety is attached to a taxane. The invention specifies that R and R1 can each independently be H or a hydrophobic organic moiety, with the condition that at least one of R and R1 is not H. The attachment of a hydrophobic organic moiety to the taxane stabilizes the association of the derivative with a lipid carrier in the plasma of animals. This innovation is particularly relevant for administering taxane derivatives to animals afflicted with cancers.

Career Highlights

Suresh Bhatia is currently associated with Cephalon, Inc., where he continues to work on advancing pharmaceutical technologies. His research has contributed to the understanding and application of taxane derivatives in cancer treatment.

Collaborations

Throughout his career, Suresh has collaborated with notable colleagues, including Eric Mayhew and J. Craig Franklin. These collaborations have further enriched his research and development efforts in the pharmaceutical industry.

Conclusion

Suresh Bhatia's work in hydrophobic taxane derivatives represents a significant advancement in cancer treatment methodologies. His innovative approach and collaboration with esteemed colleagues highlight his commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…